Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ATOVAQUONE AS LONG-TERM SUPPRESSIVE THERAPY FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS AND MULTIPLE-DRUG INTOLERANCE
Autore:
KATLAMA C; MOUTHON B; GOURDON D; LAPIERRE D; ROUSSEAU F; ALLEGRE T; DROBACHEFF C; MONLUN E; MALAMUD P; SALLES B; ROGEZ JF; GRANETBRUNELLO P; COTTE L; CHAUMENTIN G; LECLERC V; TOLLINCHI F; MOREAU J; DHIVER C; DURAND JM; XERIDAT B; RAVAUX I; REYNES J; WINTER C; RABAUD C; RAFFI F; FUZIBERT JG; VINTI H; GOUGEARD C; PERICHON I; GILQUIN J; CHAPUIS L; JEANTILS V; GREGOIRE V; CHAPUT S; DETRUCHIS P; PICARD O; CROS H; BORSALEBAS F; LAFEUILLADE A; AVEROUS S; BOUREZ JM; PRAZUCK T;
Indirizzi:
HOP LA PITIE SALPETRIERE,DEPT MALAD INFECT,47 BLVD HOP F-75013 PARIS FRANCE UNIV PARIS 06,HOP LA PITIE SALPETRIERE PARIS FRANCE GLAXO WELLCOME FRANCE LAB ISSY MOULINEAUX FRANCE HOP ST JACQUES F-25030 BESANCON FRANCE HOP ST ANDRE BORDEAUX FRANCE HOP BLIGNY BRIIS SOUS FORGES FRANCE HOP HOTEL DIEU F-69288 LYON FRANCE HOP CROIX ROUSSE F-69317 LYON FRANCE HOP F QUESNAY MANTES LA JOLIE FRANCE HOP ST JOSEPH MARSEILLE FRANCE HOP F HOUPHOUET BOIGNY MARSEILLE FRANCE HOP ST MARGUERITE MARSEILLE FRANCE POLYCLIN CLAIRVAL MARSEILLE FRANCE CHR CONCEPT MARSEILLE FRANCE HOSP GUI DE CHAULIAC MONTPELLIER FRANCE CTR HOSP INTERCOMMUNAL MONTREUIL F-93105 MONTREUIL FRANCE HOP BRABOIS NANCY FRANCE HOP HOTEL DIEU NANTES FRANCE HOP CIMIEZ F-06003 NICE FRANCE HOP BICETRE PARIS FRANCE HOP BOUCICAULT PARIS FRANCE HOP BROUSSAIS F-75674 PARIS FRANCE HOP COCHIN F-75674 PARIS FRANCE HOP JEAN VERDIER PARIS FRANCE HOP LARIBOISIERE F-75475 PARIS FRANCE HOP RAY POINCARE PARIS FRANCE HOP ST ANTOINE F-75571 PARIS FRANCE CTR HOSP PERPIGNAN PERPIGNAN FRANCE HOP CHARLES NICOLLE ROUEN FRANCE HOP CHALUCET TOULON FRANCE HOP PURPAN TOULOUSE FRANCE CTR HOSP VILLENEUVE ST GEORGES VILLENEUVE ST GEO FRANCE MAISON ARRET SANTE PARIS FRANCE
Titolo Testata:
AIDS
fascicolo: 10, volume: 10, anno: 1996,
pagine: 1107 - 1112
SICI:
0269-9370(1996)10:10<1107:AALSTF>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; CENTRAL-NERVOUS-SYSTEM; TRIMETHOPRIM-SULFAMETHOXAZOLE; PRIMARY PROPHYLAXIS; DAPSONE-PYRIMETHAMINE; EFFICACY; GONDII; SULFADIAZINE; PENTAMIDINE;
Keywords:
ATOVAQUONE; TOXOPLASMA ENCEPHALITIS; HIV INFECTION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
C. Katlama et al., "ATOVAQUONE AS LONG-TERM SUPPRESSIVE THERAPY FOR TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH AIDS AND MULTIPLE-DRUG INTOLERANCE", AIDS, 10(10), 1996, pp. 1107-1112

Abstract

Objective: To evaluate the efficacy and tolerance of atovaquone used as long-term maintenance therapy in patients with toxoplasmic encephalitis and intolerant of conventional anti-Toxoplasma therapies. Design:Uncontrolled open-label study of atovaquone given through an expandedaccess programme; statistical analysis was performed on an intent-to-treat basis. Patients: Sixty-five patients intolerant of conventional toxoplasmic encephalitis therapies - pyrimethamine, sulphadiazine or clindamycin - received atovaquone as maintenance therapy after resolution of an acute episode of toxoplasmic encephalitis. Patients were clinically and neurologically evaluated monthly. Toxoplasmic encephalitis relapse was defined as the occurrence of neurological abnormalities, except in the case of a proven alternative diagnosis. Results: Sixty-five patients were treated with atovaquone 750 mg four times daily and followed up for a mean period of 1 year. Mean CD4 lymphocytes count was29 x 10(6)/l. Prior to starting atovaquone, patients had experienced a total of 129 episodes of intolerance to conventional anti-Toxoplasmadrugs. Atovaquone was used as a single anti toxoplasmic agent in 75% of the cases. Seventeen patients (26%) experienced a toxoplasmic encephalitis relapse. Sixty-three patients (97%) were able to tolerate and continued taking atovaquone. Two patients had to discontinue therapy because of side-effects. In a multivariate analysis, only the duration of pyrimethamine-sulphadiazine therapy during the acute therapy phase of toxoplasmic encephalitis was significantly associated with a decreased risk of toxoplasmic encephalitis relapse during maintenance therapy [relative risk, 0.64 for each week of pyrimethamine-sulphadiazine; 95% confidence interval (CI), 0.42-0.96; P = 0.03]. The survival probability was 70% at 1 year after the episode of toxoplasmic encephalitis (95% CI, 57-83). Conclusion: These results suggest that atovaquone is a well-tolerated alternative anti-Toxoplasma treatment for maintenancetherapy in patients who are intolerant to conventional anti-Toxoplasma drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 05:12:11